http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Jung Ro,Jang, Ho Hee,Park, Jin Ho,Jung, Ji Hyun,Lee, Seung Sik,Park, Soo Kwon,Chi, Yong Hun,Moon, Jeong Chan,Lee, Young Mee,Kim, Sun Young,Kim, Jae-Yean,Yun, Dae-Jin,Cho, Moo Je,Lee, Kyun Oh,Lee, Blackwell Publishing Ltd 2006 The Plant journal Vol.47 No.3
<P>Summary</P><P>Using the rice <I>PEX14</I> cDNA as a bait in a yeast two-hybrid assay, two splice variants of the type I peroxisomal targeting signal (PTS1) receptor, <I>Os</I>Pex5pL and <I>Os</I>Pex5pS, were cloned from a pathogen-treated rice leaf cDNA library. The proteins were produced from a single gene by alternative splicing, which generated a full-length variant, <I>OsPEX5L</I>, and a variant that lacked exon 7, <I>OsPEX5S</I>. <I>Os</I>Pex5pL contained 11 copies of the pentapeptide motif WXXXF/Y in its N-terminus, and seven tetratricopeptide repeats in its C-terminus. Expression of <I>OsPEX5L</I> and <I>OsPEX5S</I> predominantly occurred in leaf tissues, and was induced by various stresses, such as exposure to the pathogen <I>Magnaporthe grisea</I>, and treatment with fungal elicitor, methyl viologen, NaCl or hydrogen peroxide. The Arabidopsis T-DNA insertional <I>pex5</I> mutant, <I>Atpex5</I>, which does not germinate in the absence of sucrose and was resistant to indole-3-butyric acid (IBA), was perfectly rescued by over-expression of <I>Os</I>Pex5pL, but not by <I>Os</I>Pex5pS. Using transient expression of <I>Os</I>Pex5pL and <I>Os</I>Pex5pS in the <I>Atpex5</I> mutant, we show that <I>Os</I>Pex5pL translocates both PTS1- and PTS2-containing proteins into the peroxisome by interacting with <I>Os</I>Pex7p, whereas <I>Os</I>Pex5pS is involved only in PTS1-dependent import in Arabidopsis.</P>
S-247 Impact of intracoronary injection of autologous bone marrow mesenchymal stem cells in STEMI.
( Ji Hae Lee ),( Su Seong Kim ),( Yoon Ho Lee ),( Young Je Ki ),( Jung Yean Han ),( Dong Han Kim ),( Min Goo Lee ),( Su Hyun Kim ),( Jang Hyun Cho ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Aims: The objective of the present analysis was to systematically examine the effect of intracoronary bone marrow cell (BMC) therapy on left ventricular (LV) function after successful coronary intervention for ST-segment elevation myocardial infarction with LAD territory. Methods: After successful percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction with LAD territory, 26 patients were randomly assigned to either a control group (n=13) that received optimum post-infarction medical treatment, or a bone-marrow-cell group (n=13) that received optimum medical treatment and intracoronary transfer of autologous bone-marrow cells at month after PCI. The primary endpoint was changes in left ventricular ejection fraction (LVEF) by single-photon emission computed tomography (SPECT) at 4 month. We also evaluated treatment-related adverse events. Result : Global LVEF at baseline (determined 3.5 days [SD 1.5] after PCI) was 32.3 (SD 33%) in controls and 38.3 (31%) in the bone-marrow cell group (p=0.59). The absolute improvement in the LVEF by SPECT at 4 month was greater in the BM-derived MSCs group than in the control group (8.7±8.5% vs 2.6±7.0%; p=0.037). There was no treatment-related toxicity during intracoronary administration of MSCs. No significant adverse cardiovascular events occurred during follow-up. Conclusions: Intracoronary BMC treatment leads to a moderate improvement of LVEF and reduction of LVESV at 4-month follow-up by SPECT that sustained at 12 months follow-up, without a clear significant effect on LVEDV, or infarct size.
S-248 Effects of High Dose Statin on Infarct Size Evaluated by Cardiac MRI in STEMI
( Su Seong Kim ),( Ji Hae Lee ),( Yoon Ho Lee ),( Young Je Ki ),( Jung Yean Han ),( Dong Han Kim ),( Min Goo Lee ),( Su Hyun Kim ),( Jang Hyun Cho ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Objectives: Lipid-lowering therapy with statin may reduce the risk of cardiovascular events. Our study aim was to assess a dose dependent statin effects by using a cardiac MRI for measurement of myocardial infarction size. Method : We evaluated the cardiac MRI findings of 44 consecutive patients with acute myocardial infarction who underwent a percutaneous coronary intervention in Saint Carollo hospital. Initial and follow-up cardiac MRI was checked at 1 week and 12weeks after revascularization and high dose lipid-lowering therapy (Rosuvastatin 40mg, Group I, n=24) or low dose (Rosuvastatin 5mg, Group II, n=20). In MRI analysis, we evaluated the changes of microvascular obstruction (MVO, first-pass enhancement) and infarct size (delayed enhancement) that was expressed as a percentage of left ventricle area. Results: There were no differences of baseline characteristics between groups. The mean follow-up periods of cardiac MRI was 12.9±1.2 weeks. The changes of MVO in 2 groups showed a tendency of decreasing size, but there was no significant difference (-1.90±1.49 vs. -1.52±1.83, p=0.455). However the changes of infarct size in Group II was larger than Group I (0.45±2.4 vs 2.27±3.24, p=0.013). Conclusions: Compared with a low dose, high dose treatment of rosuvastatin significantly suppressed the increasing of infarct size after revascularization in AMI.
( Sun Hyung Kang ),( Ji Hae Lee ),( Su Seong Kim ),( Yoon Ho Lee ),( Young Je Ki ),( Jung Yean Han ),( Dong Han Kim ),( Min Goo Lee ),( Su Hyun Kim ),( Jang Hyun Cho ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Objective: To assess which would be more safety and benefit between aspirin and clopidogrel at 24 months following acute myocardial infarction subjects who undergoing implantation of coronary 2nd generation Drug-Eluting stents who received dual antiplatelets therapy for 12 months . Method: We enrolled retrospectively 300 consecutive patients (mean age ; 67.1±13.6, male ; 79.3%) who has been hospitalized because of acute myocardial infarction who were treatment with implantation of coronary 2nd generation Drug-Eluting stents and received dual antiplatelets therapy for 12 months. We evaluated which is more safety and benefit between aspirin monotherapy and clopidogrel monotherapy at 24 months following dual antiplatelets therapy for 12 months. The primary endpoint was a composite of cardiac death, secondary myocardial infarction, hemorrhage stroke, ischemic stroke, gastrointestinal hemorrhage and stent thrombosis. Result Patients treated with clopidogrel had an annual 5.32% risk of ischeamic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin. These rates reflect a statistically significant (p=0.043) relative-risk reduction of 8.7% in favour of clopidogrel (95% CI 0.3-16.5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9.4%. There were no major differences in terms of safety. Adverse experience in the clopidogrel and aspirin groups were to be upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial hemorrhage (0.33% vs 0.47%), and gastrointestinal hemorrhage (0.52% vs 0.72%), respectively. Conclusion More than 2-year administration of clopidogrel to AMI subject who underwent 2nd generation DES implantation with dual antiplatelets therapy for 1 year is more effective than aspirin in reducing the combined risk of ischemic stroke, myocardial infarction, or vascular death. The Overall safety profile of clopidogrel mono therapy group is at least as good as that of medium-dose aspirin.
( Seong Taek Kim ),( Sun Hyung Kang ),( Ji Hae Lee ),( Su Seong Kim ),( Yoon Ho Lee ),( Young Je Ki ),( Jung Yean Han ),( Dong Han Kim ),( Min Goo Lee ),( Su Hyun Kim ),( Jang Hyun Cho ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Aim: Atrial enlargement has been suggested as a marker of the severity of diastolic dysfunction after acute myocardial infarction (AMI). The purpose of this study to assess the relationship between left atrial (LA) volume and outcome after AMI undergoing primary coronary intervention (PCI). This may be of importance when one assesses risk in patients with AMI undergoing PCI. Method : A total of 153 patients from December 2011 to June 2015 were recruited, prospective. Echocardiographic analyses were performed in 153 patients (92 male and 61 female, 63.4±11.7 years) with AMI undergoing PCI were studied at baseline and 12 months. We assessed LA volume index (LAVI) at baseline and 12 months after AMI. Result : Early change of Left atrial volume was an independent predictor of new onset atrial fibrillation or hospitalization for heart failure (p=0.02). In patient who survived to 12 months, LAVI increased a mean of 2.06±3.01 mL/m2 from baseline (from 25.1±7.6 to 29.0±8.1 mL/m2, p<0.001). Increased LAVI group were related to low LVEF, large left ventricle systolic and diastolic dimension and large LA size. Conclusions: Increased LAVI is a independent predictor of new onset atrial fibrillation and hospitalization for heart failure after AMI and provides prognostic information incremental to clinical data and conventional measures of LV systolic and diastolic function.